A case report of a huge congenital granular cell epulis operated under local anesthesia

Congenital granular cell epulis (CGCE) is a very rare benign soft tissue lesion of the neonate, it most frequently located on the anterior maxillary alveolar ridge. It has a female predilection. It is a tumor with no tendency to recur after excision. The exact histogenesis of this tumor remains unresolved and it may be hamartomata.Key words: Congenital granular cell tumor, gingival tumor, newborn, local anesthesi

Cervical hibernoma in a two year old boy

Hibernomas are uncommon benign soft tissue tumours mimicking brown fat. They are mostly seen in the fourth and fifth decades of life. Only few cases in the cervical area have been reported. Because of its rarity in pediatrics and diffcult diagnosis, we report a tow year-old patient with a cervical tumor. Ultrasound and computed tomography exams showed an infiltrative, with hypervascular and lipomatous features. After tumor excision,   histopathological exam confirmed the diagnosis of hibernoma or brown fat tumor. This presentation describes the characteristics of this type of tumor, rare in children

Kyste hydatique pulmonaire chez l’enfant traité par thoracoscopie: huit ans d’expérience

L'échinococcose kystique est une pathologie fréquente en zone d'endémie: pourtour méditerranéen, Afrique de l'est et l'Amérique du Sud. L'hydatidose reste à l'heure actuelle un problème majeur de santé publique. Notre travail consiste en une étude rétrospective de 27 malades opérés pour kyste hydatique pulmonaire (KHP) par thoracoscopie, au service de chirurgie pédiatrique du centre hospitalier universitaire HASSAN II à Fès, sur une période de huit ans allant de janvier 2004 au décembre 2011.Key words: Kyste hydatique, thoracoscopie, enfant, Maro

Microstructure and mechanical behavior in dissimilar 13Cr/2205 stainless steel welded pipes

Thiswork aims to investigate the microstructure and themechanical behavior of dissimilar 13Cr Supermartensitic/2205 Duplex stainless steelwelded pipes. A wide variety ofmicrostructures resulting fromboth solidification and solid state transformation is induced by the fusion welding process across the weld joint. The tensile tests show that the deformation process of the dissimilarweld joint ismainly controlled by the two basematerials: the duplex steel at the beginning of the deformation and the supermartensitic one at its end. This is confirmed by the microtensile tests showing the overmatching effect of the weld metal. The fatigue tests conducted on dissimilar welded specimens led us to conclude that the weld metal is considered as a weak link of the weld joint in the high cycle fatigue regime. This is supported by its lower fatigue limit compared to the two basematerials that exhibit a similar fatigue behavio

Le tératome cervical: A propos de 2 cas

Le tératome est une tumeur embryonnaire généralement localisé au niveau sacro-coccygien. La localisation cervicale est rare, et ne représente que3%, elle est associée à un fort taux de mortalité arrivant jusqu’à 80 % à la période néonatale du fait de l’obstruction des voies aériennes.L’immaturité n’est pas un signe de malignité quand la tumeur est prise en charge à la période néonatale. Nous rapportons 2 cas colligés au servicede chirurgie pédiatrique du CHU HASSAN II de Fès, en mettant en relief qu’il existe encore un manque de diagnostic anténatal, malgrél’amélioration de la prise en charge des nouveaux nés.Key words: Tératome cervical géant, nouveau né, chirurgi

copanlisib monotherapy activity in relapsed or refractory indolent b cell lymphoma combined analysis from phase i and ii studies

n/

A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). In Phase 1, we characterized the safety and tolerability of Isa + Cemi with planned dose de-escalation to determine the recommended Phase 2 dose (RP2D). Six patients in each cohort were treated with a starting dose of Isa + Cemi to determine the RP2D. In Phase 2, the primary endpoints were complete response in Cohort A1 (cHL anti-PD-1/programmed death-ligand 1 [PD-L1] naïve), and objective response rate in Cohorts A2 (cHL anti-PD-1/PD-L1 progressors), B (DLBCL), and C (PTCL). An interim analysis was performed when the first 18 (Cohort A1), 12 (Cohort A2), 17 (Cohort B), and 11 (Cohort C) patients in Phase 2 had been treated and followed up for 24 weeks. Isa + Cemi demonstrated a manageable safety profile with no new safety signals. No dose-limiting toxicities were observed at the starting dose; thus, the starting dose of each drug was confirmed as the RP2D. Based on the Lugano 2014 criteria, 55.6% (Cohort A1), 33.3% (Cohort A2), 5.9% (Cohort B), and 9.1% (Cohort C) of patients achieved a complete or partial response. Pharmacokinetic analyses suggested no effect of Cemi on Isa exposure. Modest clinical efficacy was observed in patients with cHL regardless of prior anti-PD-1/PD-L1 exposure. In DLBCL or PTCL cohorts, interim efficacy analysis results did not meet prespecified criteria to continue enrollment in Phase 2 Stage 2. Isa + Cemi did not have a synergistic effect in these patient populations

Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA.

Rituximab plus polychemotherapy is standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED trial compares obinutuzumab to rituximab. GAINED (NCT01659099) is an open-label, randomized phase 3 trial. Transplant-eligible patients (18-60yrs) with untreated aged-adjusted international prognostic index (aaIPI) ≥1 DLBCL were randomized (1:1) between obinutuzumab or rituximab. Patients were stratified by aaIPI (1; 2-3) and chemotherapy regimen (ACVBP; CHOP). Consolidation treatment was determined according to response assessed by centrally reviewed interim semi-quantitative PET. Responders after cycle 2 and 4 (PET2-/PET4-) received planned immuno-chemotherapy consolidation. Responders only after cycle 4 (PET2+/4-) received highdose methotrexate plus transplantation. The primary objective was an 8% improvement (HR=0.73; 80% power; alpha risk 2.5%; one-sided) in 2-year event-free survival (EFS) in the obinutuzumab arm. Events included death, progression, PET 2 or 4 positivity, modification of planned treatment. From September 20, 2012, 670 patients were enrolled (obinutuzumab n=336; rituximab n=334). 383 (57.2%) were aaIPI 2-3, 339 (50.6%) received CHOP and 324 (48.4%) received ACVBP. Median follow-up was 38.7 months. The 2-year EFS were similar in obinutuzumab and rituximab groups (59.8% vs 56.6%; p=0.123; HR=0.88). The 2-year PFS in the whole cohort was 83.1% (95%CI 80–85.8). PET2-/4- and PET2+/4- had similar 2-year PFS and OS (89.9% vs 83.9%) and 94.8% vs 92.8%). The 2-year PFS and OS for PET4+ patients were 62% and 83.1%. Grade 3-5 infections were more frequent in the obinutuzumab arm (21% vs 12%). Obinutuzumab is not superior to rituximab in untreated aaIPI≥1 DLBCL transplant-eligible patients

A resource usage efficient distributed allocation algorithm for 5G Service Function Chains

International audienceRecent evolution of networks introduce new challenges for the allocation of resources. Slicing in 5G networks allows multiple users to share a common infrastructure and the chaining of Network Function (NF)s introduces constraints on the order in which NFs are allocated. We first model the allocation of resources for Chains of NFs in 5G Slices. Then we introduce a distributed mutual exclusion algorithm to address the problem of the allocation of resources. We show with selected metrics that choosing an order of allocation of the resources that differs from the order in which resources are used can give better performances. We then show experimental results where we improve the usage rate of resources by more than 20% compared to the baseline algorithm in some cases. The experiments run on our own simulator based on SimGrid